Recruiting NA INTERVENTIONAL 1-arm NCT06251115

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Interventions QY-1-T

Updated 6 times since 2024 Last updated: May 13, 2025 Started: Jan 26, 2024 Primary completion: Jul 31, 2025 Completion: Oct 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Liver Cancer and is currently actively recruiting participants. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Recruiting NA
Nov 2024 — Jun 2025 [monthly]

Recruiting NA
Sep 2024 — Nov 2024 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
May 2024 — Jul 2024 [monthly]

Recruiting NA

▶ Show 1 earlier version

Mar 2024 — May 2024 [monthly]

Recruiting NA

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.

Data source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China